Print Page | Close Window

Press Releases

Keyword Search
 

2019 | 2018 | 2017 | 2016 | 2015
Ocular Therapeutix™ to Present at the H.C. Wainwright Global Life Sciences Conference

Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors

Ocular Therapeutix™ to Host 2019 Research & Development Day

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2018 Financial Results and Business Update

Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference

Ocular Therapeutix™ To Report Fourth Quarter and Year End 2018 Financial Results

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain